vs
PREFORMED LINE PRODUCTS CO（PLPC）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
PREFORMED LINE PRODUCTS COの直近四半期売上が大きい（$173.1M vs $160.8M、TransMedics Group, Inc.の約1.1倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 4.9%、差は60.7%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 3.6%）。TransMedics Group, Inc.の直近四半期フリーキャッシュフローが多い（$19.0M vs $11.8M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs 10.8%）
プリフォームド・ライン・プロダクツ社（PLPC）は、送配電、通信、再生可能エネルギーインフラ分野向けのエンジニアリングハードウェアや部品を設計・製造・供給し、世界各国の事業者にネットワークの信頼性と業務効率を高めるソリューションを提供している。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
PLPC vs TMDX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $173.1M | $160.8M |
| 純利益 | $8.4M | $105.4M |
| 粗利率 | 29.8% | 58.1% |
| 営業利益率 | 6.8% | 13.2% |
| 純利益率 | 4.9% | 65.6% |
| 売上前年比 | 3.6% | 32.2% |
| 純利益前年比 | -19.3% | 1436.9% |
| EPS（希薄化後） | $1.72 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $173.1M | $160.8M | ||
| Q3 25 | $178.1M | $143.8M | ||
| Q2 25 | $169.6M | $157.4M | ||
| Q1 25 | $148.5M | $143.5M | ||
| Q4 24 | $167.1M | $121.6M | ||
| Q3 24 | $147.0M | $108.8M | ||
| Q2 24 | $138.7M | $114.3M | ||
| Q1 24 | $140.9M | $96.8M |
| Q4 25 | $8.4M | $105.4M | ||
| Q3 25 | $2.6M | $24.3M | ||
| Q2 25 | $12.7M | $34.9M | ||
| Q1 25 | $11.5M | $25.7M | ||
| Q4 24 | $10.5M | $6.9M | ||
| Q3 24 | $7.7M | $4.2M | ||
| Q2 24 | $9.4M | $12.2M | ||
| Q1 24 | $9.6M | $12.2M |
| Q4 25 | 29.8% | 58.1% | ||
| Q3 25 | 29.7% | 58.8% | ||
| Q2 25 | 32.7% | 61.4% | ||
| Q1 25 | 32.8% | 61.5% | ||
| Q4 24 | 33.3% | 59.2% | ||
| Q3 24 | 31.1% | 55.9% | ||
| Q2 24 | 31.9% | 60.6% | ||
| Q1 24 | 31.3% | 61.9% |
| Q4 25 | 6.8% | 13.2% | ||
| Q3 25 | 7.4% | 16.2% | ||
| Q2 25 | 10.1% | 23.2% | ||
| Q1 25 | 8.8% | 19.1% | ||
| Q4 24 | 10.5% | 7.1% | ||
| Q3 24 | 7.1% | 3.6% | ||
| Q2 24 | 8.1% | 10.9% | ||
| Q1 24 | 8.2% | 12.8% |
| Q4 25 | 4.9% | 65.6% | ||
| Q3 25 | 1.5% | 16.9% | ||
| Q2 25 | 7.5% | 22.2% | ||
| Q1 25 | 7.8% | 17.9% | ||
| Q4 24 | 6.3% | 5.6% | ||
| Q3 24 | 5.2% | 3.9% | ||
| Q2 24 | 6.8% | 10.7% | ||
| Q1 24 | 6.8% | 12.6% |
| Q4 25 | $1.72 | $2.59 | ||
| Q3 25 | $0.53 | $0.66 | ||
| Q2 25 | $2.56 | $0.92 | ||
| Q1 25 | $2.33 | $0.70 | ||
| Q4 24 | $2.13 | $0.19 | ||
| Q3 24 | $1.54 | $0.12 | ||
| Q2 24 | $1.89 | $0.35 | ||
| Q1 24 | $1.94 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | — | — |
| 総負債低いほど良い | $38.3M | — |
| 株主資本純資産 | $475.5M | $473.1M |
| 総資産 | $653.6M | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.08× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $330.1M | ||
| Q2 24 | — | $362.8M | ||
| Q1 24 | — | $350.2M |
| Q4 25 | $38.3M | — | ||
| Q3 25 | $36.0M | — | ||
| Q2 25 | $31.8M | — | ||
| Q1 25 | $29.1M | — | ||
| Q4 24 | $20.8M | — | ||
| Q3 24 | $27.2M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | $475.5M | $473.1M | ||
| Q3 25 | $466.3M | $355.2M | ||
| Q2 25 | $460.7M | $318.1M | ||
| Q1 25 | $435.8M | $266.3M | ||
| Q4 24 | $422.3M | $228.6M | ||
| Q3 24 | $429.0M | $209.9M | ||
| Q2 24 | $416.2M | $189.9M | ||
| Q1 24 | $413.4M | $159.5M |
| Q4 25 | $653.6M | $1.1B | ||
| Q3 25 | $644.6M | $946.0M | ||
| Q2 25 | $631.5M | $890.5M | ||
| Q1 25 | $592.5M | $837.5M | ||
| Q4 24 | $573.9M | $804.1M | ||
| Q3 24 | $592.0M | $785.6M | ||
| Q2 24 | $572.6M | $758.6M | ||
| Q1 24 | $586.1M | $723.8M |
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.08× | — | ||
| Q1 24 | 0.13× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $21.9M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $11.8M | $19.0M |
| FCFマージンFCF / 売上 | 6.8% | 11.8% |
| 設備投資強度設備投資 / 売上 | 5.9% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 2.60× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $33.3M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $21.9M | $34.5M | ||
| Q3 25 | $18.9M | $69.6M | ||
| Q2 25 | $26.9M | $91.6M | ||
| Q1 25 | $5.7M | $-2.9M | ||
| Q4 24 | $24.1M | $19.7M | ||
| Q3 24 | $9.4M | $6.9M | ||
| Q2 24 | $28.3M | $25.7M | ||
| Q1 24 | $5.8M | $-3.4M |
| Q4 25 | $11.8M | $19.0M | ||
| Q3 25 | $8.3M | $61.9M | ||
| Q2 25 | $18.6M | $82.5M | ||
| Q1 25 | $-5.3M | $-29.9M | ||
| Q4 24 | $20.6M | $6.1M | ||
| Q3 24 | $5.8M | $-41.3M | ||
| Q2 24 | $24.6M | $2.0M | ||
| Q1 24 | $1.8M | $-47.6M |
| Q4 25 | 6.8% | 11.8% | ||
| Q3 25 | 4.7% | 43.1% | ||
| Q2 25 | 10.9% | 52.4% | ||
| Q1 25 | -3.6% | -20.8% | ||
| Q4 24 | 12.3% | 5.0% | ||
| Q3 24 | 3.9% | -38.0% | ||
| Q2 24 | 17.7% | 1.7% | ||
| Q1 24 | 1.3% | -49.2% |
| Q4 25 | 5.9% | 9.7% | ||
| Q3 25 | 6.0% | 5.3% | ||
| Q2 25 | 4.9% | 5.8% | ||
| Q1 25 | 7.4% | 18.8% | ||
| Q4 24 | 2.1% | 11.2% | ||
| Q3 24 | 2.4% | 44.3% | ||
| Q2 24 | 2.7% | 20.8% | ||
| Q1 24 | 2.8% | 45.6% |
| Q4 25 | 2.60× | 0.33× | ||
| Q3 25 | 7.21× | 2.86× | ||
| Q2 25 | 2.12× | 2.62× | ||
| Q1 25 | 0.49× | -0.11× | ||
| Q4 24 | 2.30× | 2.87× | ||
| Q3 24 | 1.22× | 1.63× | ||
| Q2 24 | 3.02× | 2.11× | ||
| Q1 24 | 0.60× | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PLPC
セグメントデータなし
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
